Different Durations of Adjuvant Anastrozole Therapy After 2 to 3 Years Tamoxifen Therapy in Breast Cancer (DATA)
A Prospective Randomised, Open, Multicentre, Phase III Study to Assess Different Durations of Anastrozole Therapy After 2 to 3 Years Tamoxifen as Adjuvant Therapy in Postmenopausal Women With Breast Cancer.
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 3
Contacts and Locations
Study Locations
-
-
-
Alkmaar, Netherlands
- Research Site
-
Almelo, Netherlands
- Research Site
-
Almere, Netherlands
- Research Site
-
Amersfoort, Netherlands
- Research Site
-
Amstelveen, Netherlands
- Research Site
-
Amsterdam, Netherlands
- Research Site
-
Apeldoorn, Netherlands
- Research Site
-
Arnhem, Netherlands
- Research Site
-
Bergen Op Zoom, Netherlands
- Research Site
-
Beugen, Netherlands
- Research Site
-
Breda, Netherlands
- Research Site
-
Capelle Aan Den IJssel, Netherlands
- Research Site
-
Den Bosch, Netherlands
- Research Site
-
Den Haag, Netherlands
- Research Site
-
Deventer, Netherlands
- Research Site
-
Dirksland, Netherlands
- Research Site
-
Doetinchem, Netherlands
- Research Site
-
Dordrecht, Netherlands
- Research Site
-
Drachten, Netherlands
- Research Site
-
Ede, Netherlands
- Research Site
-
Eindhoven, Netherlands
- Research Site
-
Emmen, Netherlands
- Research Site
-
Enschede, Netherlands
- Research Site
-
Geldrop, Netherlands
- Research Site
-
Geleen, Netherlands
- Research Site
-
Goes, Netherlands
- Research Site
-
Gorinchem, Netherlands
- Research Site
-
Gouda, Netherlands
- Research Site
-
Haarlem, Netherlands
- Research Site
-
Hardenberg, Netherlands
- Research Site
-
Heerenveen, Netherlands
- Research Site
-
Heerlen, Netherlands
- Research Site
-
Hengelo, Netherlands
- Research Site
-
Hilversum, Netherlands
- Research Site
-
Hoofddorp, Netherlands
- Research Site
-
Hoogeveen, Netherlands
- Research Site
-
Hoorn, Netherlands
- Research Site
-
Leeuwarden, Netherlands
- Research Site
-
Leiden, Netherlands
- Research Site
-
Leidschendam, Netherlands
- Research Site
-
Maastricht, Netherlands
- Research Site
-
Nieuwegein, Netherlands
- Research Site
-
Nijmegen, Netherlands
- Research Site
-
Purmerend, Netherlands
- Research Site
-
Roermond, Netherlands
- Research Site
-
Roosendaal, Netherlands
- Research Site
-
Rotterdam, Netherlands
- Research Site
-
Schiedam, Netherlands
- Research Site
-
Sneek, Netherlands
- Research Site
-
Spijkenisse, Netherlands
- Research Site
-
Stadskanaal, Netherlands
- Research Site
-
Terneuzen, Netherlands
- Research Site
-
Tiel, Netherlands
- Research Site
-
Tilburg, Netherlands
- Research Site
-
Uden, Netherlands
- Research Site
-
Utrecht, Netherlands
- Research Site
-
Veldhoven, Netherlands
- Research Site
-
Venlo, Netherlands
- Research Site
-
Vlissingen, Netherlands
- Research Site
-
Winschoten, Netherlands
- Research Site
-
Winterswijk, Netherlands
- Research Site
-
Woerden, Netherlands
- Research Site
-
Zaandam, Netherlands
- Research Site
-
Zevenaar, Netherlands
- Research Site
-
Zoetermeer, Netherlands
- Research Site
-
Zutphen, Netherlands
- Research Site
-
Zwolle, Netherlands
- Research Site
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- postmenopausal patients with hormone receptor positive breast cancer who have already received 2 to 3 years of adjuvant tamoxifen, and who never had signs of loco-regional recurrences or distant metastasis
Exclusion Criteria:
- Previous hormonal therapy as adjuvant breast cancer treatment besides tamoxifen.
- Previous history of invasive breast cancer within the last 10 years, other then the breast cancer that is currently treated with tamoxifen
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: 1
6 years adjuvant anastrozole therapy
|
1 mg once daily oral dose
Other Names:
|
|
Experimental: 2
3 years adjuvant anastrozole therapy
|
1 mg once daily oral dose
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
To assess the disease free survival (DFS) with 6 years of adjuvant anastrozole compared with 3 years of adjuvant anastrozole in postmenopausal hormone sensitive breast cancer patients, subsequent to 2 to 3 years of adjuvant tamoxifen
Time Frame: After 9 years for the group with 6 years of adjuvant anastrozol, subsequent to 2 to 3 years of adjuvant tamoxifen or after 6 years for the group with 3 years of adjuvant anastrozole subsequent to 2 to 3 years of adjuvant tamoxifen
|
After 9 years for the group with 6 years of adjuvant anastrozol, subsequent to 2 to 3 years of adjuvant tamoxifen or after 6 years for the group with 3 years of adjuvant anastrozole subsequent to 2 to 3 years of adjuvant tamoxifen
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
To compare the incidence of contralateral breast cancer after 6 years versus 3 years adjuvant anastrozole, subsequent to 2 to 3 years of tamoxifen
Time Frame: After 9 years for the group with 6 years of adjuvant anastrozol, subsequent to 2 to 3 years of adjuvant tamoxifen or after 6 years for the group with 3 years of adjuvant anastrozole subsequent to 2 to 3 years of adjuvant tamoxifen
|
After 9 years for the group with 6 years of adjuvant anastrozol, subsequent to 2 to 3 years of adjuvant tamoxifen or after 6 years for the group with 3 years of adjuvant anastrozole subsequent to 2 to 3 years of adjuvant tamoxifen
|
|
|
To compare the overall survival after 6 years versus 3 years adjuvant anastrozole, subsequent to 2 to 3 years of tamoxifen
Time Frame: After 9 years for the group with 6 years of adjuvant anastrozol, subsequent to 2 to 3 years of adjuvant tamoxifen or after 6 years for the group with 3 years of adjuvant anastrozole subsequent to 2 to 3 years of adjuvant tamoxifen
|
After 9 years for the group with 6 years of adjuvant anastrozol, subsequent to 2 to 3 years of adjuvant tamoxifen or after 6 years for the group with 3 years of adjuvant anastrozole subsequent to 2 to 3 years of adjuvant tamoxifen
|
|
|
To compare toxicity of 6 years versus 3 years of adjuvant anastrozole in postmenopausal hormone sensitive breast cancer patients, subsequent to 2 to 3 years of tamoxifen
Time Frame: After 9 years for the group with 6 years of adjuvant anastrozol, subsequent to 2 to 3 years of adjuvant tamoxifen or after 6 years for the group with 3 years of adjuvant anastrozole subsequent to 2 to 3 years of adjuvant tamoxifen
|
After 9 years for the group with 6 years of adjuvant anastrozol, subsequent to 2 to 3 years of adjuvant tamoxifen or after 6 years for the group with 3 years of adjuvant anastrozole subsequent to 2 to 3 years of adjuvant tamoxifen
|
|
|
To determine regional differences in the initial treatment of breast cancer retrospectively by collecting baseline information on initial therapies.
Time Frame: After 9 years
|
Aspects of the initial treatment that will be investigated are e.g. the kind of surgery performed (breast saving or mastectomy) and whether or not chemotherapy is given and which chemotherapy was used in postmenopausal patients in relation to the primary tumour and patient characteristics.
|
After 9 years
|
|
To compare the cost effectiveness of 3 years versus 6 years adjuvant anastrozole therapy, after subsequent 2 to 3 years of adjuvant tamoxifen treatment.
Time Frame: After 9 years for the group with 6 years of adjuvant anastrozol, subsequent to 2 to 3 years of adjuvant tamoxifen or after 6 years for the group with 3 years of adjuvant anastrozole subsequent to 2 to 3 years of adjuvant tamoxifen
|
After 9 years for the group with 6 years of adjuvant anastrozol, subsequent to 2 to 3 years of adjuvant tamoxifen or after 6 years for the group with 3 years of adjuvant anastrozole subsequent to 2 to 3 years of adjuvant tamoxifen
|
|
|
To assess patterns of care in The Netherlands in prevention, detection and treatment of osteoporosis in postmenopausal women with breast cancer treated with adjuvant anastrozole.
Time Frame: After 9 years
|
After 9 years
|
|
|
To relate the number of osteoporotic fractures during and following treatment with adjuvant anastrozole with the compliance to osteoporotic guidelines.
Time Frame: After 9 years
|
After 9 years
|
|
|
To analyse occurrence of distant (bone) metastases in relation to occurrence of osteopenia and osteoporosis, and in relation to use of supplements and therapy for reduced BMD.
Time Frame: After 9 years
|
After 9 years
|
Collaborators and Investigators
Sponsor
Sponsor
Publications and helpful links
General Publications
- van Hellemond IEG, Smorenburg CH, Peer PGM, Swinkels ACP, Seynaeve CM, van der Sangen MJC, Kroep JR, de Graaf H, Honkoop AH, Erdkamp FLG, van den Berkmortel FWPJ, de Boer M, de Roos WK, Linn SC, Imholz ALT, Tjan-Heijnen VCG; Dutch Breast Cancer Research Group (BOOG). Assessment and management of bone health in women with early breast cancer receiving endocrine treatment in the DATA study. Int J Cancer. 2019 Sep 1;145(5):1325-1333. doi: 10.1002/ijc.32205. Epub 2019 Mar 4.
- van Hellemond IEG, Vriens IJH, Peer PGM, Swinkels ACP, Smorenburg CH, Seynaeve CM, van der Sangen MJC, Kroep JR, de Graaf H, Honkoop AH, Erdkamp FLG, van den Berkmortel FWPJ, de Boer M, de Roos WK, Linn SC, Imholz ALT, Tjan-Heijnen VCG; Dutch Breast Cancer Research Group (BOOG). Efficacy of anastrozole after tamoxifen in early breast cancer patients with chemotherapy-induced ovarian function failure. Int J Cancer. 2019 Jul 1;145(1):274-283. doi: 10.1002/ijc.32093. Epub 2019 Jan 16.
- Tjan-Heijnen VCG, van Hellemond IEG, Peer PGM, Swinkels ACP, Smorenburg CH, van der Sangen MJC, Kroep JR, De Graaf H, Honkoop AH, Erdkamp FLG, van den Berkmortel FWPJ, de Boer M, de Roos WK, Linn SC, Imholz ALT, Seynaeve CM; Dutch Breast Cancer Research Group (BOOG) for the DATA Investigators. Extended adjuvant aromatase inhibition after sequential endocrine therapy (DATA): a randomised, phase 3 trial. Lancet Oncol. 2017 Nov;18(11):1502-1511. doi: 10.1016/S1470-2045(17)30600-9. Epub 2017 Oct 12. Erratum In: Lancet Oncol. 2017 Nov;18(11):e642.
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Estimate)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Skin Diseases
- Neoplasms
- Neoplasms by Site
- Breast Diseases
- Breast Neoplasms
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Enzyme Inhibitors
- Antineoplastic Agents
- Hormones, Hormone Substitutes, and Hormone Antagonists
- Antineoplastic Agents, Hormonal
- Hormone Antagonists
- Aromatase Inhibitors
- Steroid Synthesis Inhibitors
- Estrogen Antagonists
- Anastrozole
Other Study ID Numbers
Other Study ID Numbers
- D5392NL003
- EUDRAct No: 2005-006167-31
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.